Syed Akbar N, Landrum Kevin, Ganley Theodore J
Division of Orthopaedics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
J Pediatr Soc North Am. 2024 Feb 28;6:100008. doi: 10.1016/j.jposna.2024.100008. eCollection 2024 Feb.
Pediatric sports participation and subsequent injuries have increased in parallel. Additionally, pediatric athletes and families are highly invested in rapid return to pre-injury status and the ability to sustain high impact loads and tension. Recently, an increase and diversification of biologically derived substances, known as orthobiologics, have been used to accelerate tissue healing. While commonly used in adults, the indications are ambiguous, and evidence for effectiveness is conflicting. Despite this, an interest in pediatric indications for orthobiologics has increased as both a standalone intervention and as a supplement to current treatment. There is a dearth of literature pertaining to the pediatric population, which warrants a review of what research has been performed. The purpose of this review was to critically examine the indications and results of orthobiologics in immature athletes. Much of the existing literature is composed of case studies or studies performed with relatively small sample sizes. As such, we believe more research is needed in almost every context for absolute guidelines and recommendations to be established. While orthobiologics have been purported to provide a significant healing benefit to augment the treatment of sports injuries, we find no additional benefit compared to standard treatment.
1)While orthobiologics have been used in small sample sizes to provide additional healing for pediatric patients being treated for sports-related injuries, there is little research in large cohorts of pediatric athletes.2)Adding to the ambiguity, the literature that does exist presents conflicting findings regarding benefits of orthobiologics.3)Orthobiologics have the potential to provide significant advanced healing benefits, however significantly more research of larger cohort size, higher evidence level, and a pediatric-only population is necessary for absolute guidelines and recommendations to be made.
儿童参与体育运动及随后受伤的情况同步增加。此外,儿童运动员及其家庭高度关注能否迅速恢复到受伤前状态以及承受高冲击负荷和张力的能力。最近,被称为生物制剂的生物衍生物质的种类增加且用途多样,已被用于加速组织愈合。虽然生物制剂在成人中常用,但其适应证尚不明确,有效性证据也相互矛盾。尽管如此,对生物制剂在儿童中的应用适应证的兴趣有所增加,既作为一种独立干预措施,也作为当前治疗的补充。关于儿童群体的文献匮乏,这就需要对已开展的研究进行综述。本综述的目的是严格审查生物制剂在未成熟运动员中的适应证和结果。现有文献大多由案例研究或样本量相对较小的研究组成。因此,我们认为几乎在每种情况下都需要更多研究,才能制定出绝对的指南和建议。虽然有人声称生物制剂能为增强运动损伤治疗提供显著的愈合益处,但我们发现与标准治疗相比并无额外益处。
1)虽然生物制剂已被用于小样本量研究,为因运动相关损伤接受治疗的儿科患者提供额外愈合效果,但针对大量儿科运动员的研究较少。2)更不明确的是,现有文献对于生物制剂的益处呈现出相互矛盾的结果。3)生物制剂有可能提供显著的促进愈合益处,然而,要制定绝对的指南和建议,还需要对更大样本量、更高证据水平且仅针对儿科人群进行更多研究。